skip to content
Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness Preview this item
ClosePreview this item
Checking...

Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness

Author: Canadian Agency for Drugs and Technologies in Health.
Publisher: [Ottawa, Ont.] : Canadian Agency for Drugs and Technologies in Health, 2011
Series: Rapid response report.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Osteoarthritis (OA) is a chronic condition involving degeneration of cartilage within the joints. It is the most common form of arthritis and is associated with pain, substantial disability and poor quality of life. 1 Rheumatoid arthritis (RA) is a systemic auto-immune disorder, involving persistent joint inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) play an important role in controlling the symptoms  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 780140531
Notes: "07 December 2011."
Description: 1 online resource (20 pages) : tables, digital file.
Series Title: Rapid response report.
Responsibility: [prepared by Canadian Agency for Drugs and Technologies in Health].
More information:

Abstract:

Osteoarthritis (OA) is a chronic condition involving degeneration of cartilage within the joints. It is the most common form of arthritis and is associated with pain, substantial disability and poor quality of life. 1 Rheumatoid arthritis (RA) is a systemic auto-immune disorder, involving persistent joint inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) play an important role in controlling the symptoms of arthritis including OA and RA, lower back pain and soft tissue pain, by blocking cyclooxygenase (COX) enzymes. Two COX isoenzymes, COX-1 and COX-2, have important roles in the effects of NSAIDs. COX-1 mediates the mucosal protection of the gastrointestinal (GI) mucosa, while COX-2 is found throughout the body, including joint and muscle and mediates effects on pain and inflammation. By blocking COX-2, NSAIDs reduce pain from different etiologies, such as arthritis, lower back pain, minor injuries and soft-tissue rheumatism. 1 NSAIDs that block both COX-1 and COX-2 enzymes are called non-COX-2 selective NSAIDs (nsNSAIDs) and can cause GI bleeding. NSAIDs that target only the COX-2 enzyme, such as celecoxib, are called COX-2 selective NSAIDs and are deemed safer with regards to GI bleeding than nsNSAIDs. Studies found, however, that they may increase the risk of cardiovascular (CV) adverse events. Celecoxib is a commonly used COX-2 selective inhibitor and is indicated for the relief of symptoms associated with OA, RA and ankylosing spondylitis (AS). The purpose of this report is to review the evidence regarding the use of celecoxib in adult patients with OA, RA or other diseases that require pain management. Its clinical effectiveness, safety, and cost-effectiveness are compared with those of nsNSAIDs.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/780140531<\/a>> # Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:MediaObject<\/a>, schema:Book<\/a>, schema:CreativeWork<\/a> ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"780140531<\/span>\" ;\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Place\/ottawa_ont<\/a>> ; # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/id.loc.gov\/vocabulary\/countries\/onc<\/a>> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh97003721<\/a>> ; # Pain--Treatment<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/dewey.info\/class\/616.723061\/e19\/<\/a>> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/therapeutic_use_cyclooxygenase_2_inhibitors<\/a>> ; # therapeutic use.--Cyclooxygenase 2 Inhibitors<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/pain_treatment<\/a>> ; # Pain--Treatment<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/osteoarthritis_drug_therapy<\/a>> ; # Osteoarthritis--drug therapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/celecoxib_evaluation<\/a>> ; # Celecoxib--Evaluation<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/osteoarthritis_chemotherapy<\/a>> ; # Osteoarthritis--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/nonsteroidal_anti_inflammatory_agents<\/a>> ; # Nonsteroidal anti-inflammatory agents<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/therapeutic_use_anti_inflammatory_agents_non_steroidal<\/a>> ; # therapeutic use.--Anti-Inflammatory Agents, Non-Steroidal<\/span>\n\u00A0\u00A0\u00A0\nschema:bookFormat<\/a> schema:EBook<\/a> ;\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/viaf.org\/viaf\/145374402<\/a>> ; # Canadian Agency for Drugs and Technologies in Health.<\/span>\n\u00A0\u00A0\u00A0\nschema:copyrightYear<\/a> \"2011<\/span>\" ;\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2011<\/span>\" ;\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2012<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"Osteoarthritis (OA) is a chronic condition involving degeneration of cartilage within the joints. It is the most common form of arthritis and is associated with pain, substantial disability and poor quality of life. 1 Rheumatoid arthritis (RA) is a systemic auto-immune disorder, involving persistent joint inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) play an important role in controlling the symptoms of arthritis including OA and RA, lower back pain and soft tissue pain, by blocking cyclooxygenase (COX) enzymes. Two COX isoenzymes, COX-1 and COX-2, have important roles in the effects of NSAIDs. COX-1 mediates the mucosal protection of the gastrointestinal (GI) mucosa, while COX-2 is found throughout the body, including joint and muscle and mediates effects on pain and inflammation. By blocking COX-2, NSAIDs reduce pain from different etiologies, such as arthritis, lower back pain, minor injuries and soft-tissue rheumatism. 1 NSAIDs that block both COX-1 and COX-2 enzymes are called non-COX-2 selective NSAIDs (nsNSAIDs) and can cause GI bleeding. NSAIDs that target only the COX-2 enzyme, such as celecoxib, are called COX-2 selective NSAIDs and are deemed safer with regards to GI bleeding than nsNSAIDs. Studies found, however, that they may increase the risk of cardiovascular (CV) adverse events. Celecoxib is a commonly used COX-2 selective inhibitor and is indicated for the relief of symptoms associated with OA, RA and ankylosing spondylitis (AS). The purpose of this report is to review the evidence regarding the use of celecoxib in adult patients with OA, RA or other diseases that require pain management. Its clinical effectiveness, safety, and cost-effectiveness are compared with those of nsNSAIDs.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/1088348503<\/a>> ;\u00A0\u00A0\u00A0\nschema:genre<\/a> \"Electronic books<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:inLanguage<\/a> \"en<\/span>\" ;\u00A0\u00A0\u00A0\nschema:isPartOf<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Series\/rapid_response_report_summary_with_critical_appraisal<\/a>> ; # Rapid response report, summary with critical appraisal<\/span>\n\u00A0\u00A0\u00A0\nschema:isPartOf<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Series\/rapid_response_report<\/a>> ; # Rapid response report.<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"780140531<\/span>\" ;\u00A0\u00A0\u00A0\nschema:publication<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/780140531#PublicationEvent\/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2011_saint_lazare_quebec_canadian_electronic_library_2012<\/a>> ;\u00A0\u00A0\u00A0\nschema:publisher<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> ; # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\nschema:url<\/a> <https:\/\/deslibris.ca\/ID\/230838<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/books.scholarsportal.info\/viewdoc.html?id=\/ebooks\/ebooks1\/gibson_chrc\/2012-03-31\/1\/10527620<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/deslibris.ca\/ID\/230838<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/public.ebookcentral.proquest.com\/choice\/publicfullrecord.aspx?p=3278445<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/site.ebrary.com\/id\/10527620<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/proxy.library.carleton.ca\/login?url=http:\/\/books.scholarsportal.info\/viewdoc.html?id=\/ebooks\/ebooks1\/gibson_chrc\/2012-03-31\/1\/10527620<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <https:\/\/login.library.sheridanc.on.ca\/login?url=https:\/\/www.deslibris.ca\/ID\/230838<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/www.deslibris.ca\/ID\/230838<\/a>> ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/780140531<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/dewey.info\/class\/616.723061\/e19\/<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:Agent<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Canadian Agency for Drugs and Technologies in Health<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Place\/ottawa_ont<\/a>> # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Ottawa, Ont.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Series\/rapid_response_report<\/a>> # Rapid response report.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:PublicationSeries<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/www.worldcat.org\/oclc\/780140531<\/a>> ; # Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Rapid response report.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Series\/rapid_response_report_summary_with_critical_appraisal<\/a>> # Rapid response report, summary with critical appraisal<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:PublicationSeries<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/www.worldcat.org\/oclc\/780140531<\/a>> ; # Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Rapid response report, summary with critical appraisal<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/celecoxib_evaluation<\/a>> # Celecoxib--Evaluation<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh00009577<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Celecoxib--Evaluation<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/nonsteroidal_anti_inflammatory_agents<\/a>> # Nonsteroidal anti-inflammatory agents<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Nonsteroidal anti-inflammatory agents<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/osteoarthritis_chemotherapy<\/a>> # Osteoarthritis--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh85095960<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Osteoarthritis--Chemotherapy<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/osteoarthritis_drug_therapy<\/a>> # Osteoarthritis--drug therapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Osteoarthritis--drug therapy<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/pain_treatment<\/a>> # Pain--Treatment<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Pain--Treatment<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/therapeutic_use_anti_inflammatory_agents_non_steroidal<\/a>> # therapeutic use.--Anti-Inflammatory Agents, Non-Steroidal<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"therapeutic use.--Anti-Inflammatory Agents, Non-Steroidal<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Topic\/therapeutic_use_cyclooxygenase_2_inhibitors<\/a>> # therapeutic use.--Cyclooxygenase 2 Inhibitors<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"therapeutic use.--Cyclooxygenase 2 Inhibitors<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/authorities\/subjects\/sh97003721<\/a>> # Pain--Treatment<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Pain--Treatment<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/vocabulary\/countries\/onc<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\ndcterms:identifier<\/a> \"onc<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/proxy.library.carleton.ca\/login?url=http:\/\/books.scholarsportal.info\/viewdoc.html?id=\/ebooks\/ebooks1\/gibson_chrc\/2012-03-31\/1\/10527620<\/a>>\u00A0\u00A0\u00A0\nrdfs:comment<\/a> \"Scholars Portal Books<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/viaf.org\/viaf\/145374402<\/a>> # Canadian Agency for Drugs and Technologies in Health.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Canadian Agency for Drugs and Technologies in Health.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/780140531<\/a>>\u00A0\u00A0\u00A0\u00A0a \ngenont:InformationResource<\/a>, genont:ContentTypeGenericResource<\/a> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/www.worldcat.org\/oclc\/780140531<\/a>> ; # Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs : a review of the clinical effectiveness, safety, and cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:dateModified<\/a> \"2020-03-27<\/span>\" ;\u00A0\u00A0\u00A0\nvoid:inDataset<\/a> <http:\/\/purl.oclc.org\/dataset\/WorldCat<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/780140531#PublicationEvent\/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2011_saint_lazare_quebec_canadian_electronic_library_2012<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:PublicationEvent<\/a> ;\u00A0\u00A0\u00A0\nschema:location<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Place\/ottawa_ont<\/a>> ; # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\nschema:organizer<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1088348503#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> ; # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\nschema:startDate<\/a> \"2011<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n